Glyburide
Sulfonylurea
NADAC/unit
$0.0581
No Shortage
Tier 1: 125.2%
PA Req: 66.6%
7 Manufacturers
25 ANDAs
Glyburide stimulates insulin release from the pancreas to lower blood sugar.
Active Shortages
2025-06-10 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2025-06-10 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2025-06-10 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
2025-06-10 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
Generic Manufacturers
CADILA PHARMACEUTICALS LTDEPIC PHARMA LLCHERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INCIMPAX LABORATORIES INCORIENT PHARMA CO LTDSANOFI AVENTIS US LLCTEVA PHARMACEUTICALS USA INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.